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Abstract In this study, we attempted to assess the
interactions of resveratrol, a natural compound present
in various plant species, with the purine analogues
fludarabine and cladribine in terms of their effects on
DNA damage and apoptosis in chronic lymphocytic
leukemia (CLL) cells. The experiments were performed
ex vivo using short-term cell cultures of blood and bone
marrow cells from newly diagnosed untreated patients.
We analyzed the expression of active caspase-3 and the
BCL-2/BAX ratio as markers of apoptosis and the
expression of phosphorylated histone H2AX (γH2AX)
and activated ATM kinase, which are reporters of DNA
damage. The results of our study revealed that resver-
atrol induced apoptosis in CLL cells in a tumor-specific
manner but did not affect non-leukemic cells, and
apoptosis was associated with a decreased BCL2/BAX
ratio. Here, we report for the first time that both
resveratrol + fludarabine and resveratrol + cladribine
caused a higher rate of apoptosis in comparison to the
rate caused by a single drug. The percentage of
apoptotic cells induced by resveratrol alone was higher
in the group of patients with better prognostic markers
than in those with worse prognostic markers. However,
the rates of apoptosis caused by resveratrol combined
with purine analogues were independent of ZAP-70 and
CD38 expression and the clinical state of the disease;
they were only dependent on the presence of high-risk
cytogenetic abnormalities. We also observed an increase
in γH2AX expression together with a rise in activated
ATM in most of the analyzed samples. The obtained
results indicate that resveratrol might warrant further
study as a new therapeutic option for CLL patients.
This naturally occurring substance may be used as a
single agent, especially in older persons for whom there
are some limitations for the use of aggressive treatment.
On the other hand, a lower purine analogue dose could
potentially be used in combination with resveratrol
because of their combined effect. One of the mecha-
nisms of action of resveratrol is the induction of DNA
damage, which ultimately leads to apoptosis.
Keywords Apoptosis.CLL.DNA damage.
Purine analogues.Resveratrol
Introduction
Chronic lymphocytic leukemia (CLL) is the most
frequent type of adult leukemia in western countries
and is characterized by the accumulation of monoclonal,
mainly B, lymphocytes in blood, bone marrow, and
lymphoid organs [1, 2]. Despite the recent introduction of
many therapeutic regimens, CLL is still an incurable
disorder. It can be effectively treated with purine ana-
logues, glucocorticoids, alkylating agents, or monoclonal
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refractory disease have limited therapeutic options. Thus,
there is an urgent need to discover novel, less toxic, and
more effective drugs for CLL patients. Among other
options, the use of immunomodulatory agents or plant-
derived substances has been reported to improve the
results of CLL treatment.
Resveratrol (trans-3,4′,5-trihyrdoxystilbene) is a natural
compound that is present in various plant species and is
relatively abundant in vines. It has many biological and
pharmaceutical properties [3–5], and the most biologically
active isomer is trans-resveratrol. Primary research on this
substance began with the observation that a low incidence
of cardiovascular diseases may co-exist with a high-fat diet
and moderate consumption of red wine (it is known as the
French paradox) [6]. The mechanisms of cardiovascular
protection caused by resveratrol involve inhibition of
platelet aggregation, arterial vasodilatation mediated by
nitric oxide release, favorable changes in lipid metabolism,
antioxidant effects, stimulation of angiogenesis, and induc-
tion of cardioprotective protein expression [6–8]. It has also
been suggested that resveratrol has therapeutic potential for
allergy and neurological disorders [9, 10]. The anticancer
properties of this naturally occurring substance were first
noticed when Jang et al. [11] demonstrated its cancer-
chemopreventive and cytostatic properties via the initiation,
promotion, and progression of carcinogenesis. Resveratrol
was found to inhibit proliferation and induce apoptosis in
several human cancer cells, including B-cell malignancies
[12].
In the present study, we attempted to explore whether
resveratrol could induce apoptosis in CLL leukemic cells
and non-leukemic lymphocytes derived from peripheral
blood and bone marrow and to assess the interactions of
resveratrol with two purine analogues, fludarabine and
cladribine, with respect to their effect on apoptosis in CLL
cells. We also investigated whether resveratrol had an effect
on DNA damage. Subsequently, apoptosis and DNA
damage markers were correlated with CLL prognostic
factors, such as ZAP-70 and CD38 expression, clinical
states according to the Rai classification, and cytogenetic
abnormalities.
The experiments were performed using short-term
cell cultures of peripheral blood and bone marrow
supplemented with resveratrol and peripheral blood
supplemented with resveratrol in combination with purine
analogues. We analyzed the active caspase-3 expression as
a marker of apoptosis and the intracellular expression
levels of BCL-2 and BAX as regulators of apoptosis.
DNA damage was assessed by measuring the expression
levels of phosphorylated histone H2AX (named γH2AX)
and activated ATM kinase (ataxia telangiectasia mutated
kinase).
Material and methods
Patients
Eighteen newly diagnosed, untreated CLL patients were
enrolled in the study. The diagnosis of CLL was based on
clinical examination and morphological and immunological
criteria. Peripheral blood and bone marrow samples were
obtained from the patients following the provision of
informed consent. Peripheral blood samples from healthy
donors were used as controls.
Cell isolation and culture
Peripheral blood and bone marrow mononuclear cells were
isolated by density gradient centrifugation using Biocoll
Separating Solution (Biochrom AG, Berlin, Germany).
After two washes with phosphate-buffered saline (PBS),
the cells were resuspended in culture medium consisting of
RPMI 1640 with 2 mM L-glutamine, 100 units/ml penicil-
lin, 100 μg/ml streptomycin, and 10% fetal calf serum
(FCS) at a final density of 2×10
6 cells/ml. This culture
medium was supplemented with 40 μM resveratrol, 1 μg/
ml fludarabine, 1.4 μg/ml cladribine, or a mixture of
resveratrol and fludarabine or resveratrol and cladribine.
We selected a concentration of 40 μM resveratrol based on
preliminary experiments in CLL cultures in which this
concentration of resveratrol revealed a significant induction
of apoptosis with spontaneous apoptosis that did not exceed
50% of the total cell culture. To obtain stock solutions,
resveratrol was dissolved in 0.1% DMSO. All reagents
were obtained from Sigma-Aldrich Chemie GmbH, Stein-
heim, Germany. The cells were cultured at 37°C in a 5%
CO2 atmosphere. Cells were exposed to the drugs for 0, 2,
and 24 h in culture, and cells treated for 2 h were analyzed
for H2AX phosphorylation and ATM activation, whereas
those treated for 24 h were assessed for the frequency of
apoptosis. H2AX phosphorylation induced by external
DNA damaging agents was observed early during the
treatment (up to 2 h), whereas, at later time points (>3 h),
H2AX phosphorylation was associated with apoptosis [13].
The respective cell samples incubated in absence of any
drug or in the presence of the resveratrol solvent DMSO for
periods of time equivalent to the drug-treated cells were
considered negative controls.
Immunocytochemical detection of active caspase-3
and BCL-2 and BAX proteins
The blood and bone marrow samples that had been
treated in culture with resveratrol, fludarabine, cladri-
bine, or a mixture of these drugs (∼10
5 cells) were
initially incubated for 15 min with anti-CD19 PE-Cy5 and
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(DAKO, Glostrup, Denmark) at room temperature. Sub-
sequently, the cells were subjected to fixation and
permeabilization procedures using an IntraPrep kit (Immu-
notech, Marseilles, France) according to the manufac-
turer’s instructions. The cells were then incubated with
PE-conjugated anti-active caspase-3 mAb (Pharmingen,
Franklin Lakes, NJ, USA), FITC-conjugated anti-
intracellular BAX mAb (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), PE-conjugated anti-intracellular BCL-2
mAb (Pharmingen) or an isotype-matched negative con-
trol (DAKO) in the dark at room temperature for 15 min.
Blood samples obtained from healthy donors that had been
treated in culture with resveratrol were initially incubated
with anti-CD19 and anti-CD3 mAb, followed by fixation,
permeabilization, and staining with anti-active caspase-3
mAb.
Immunocytochemical detection of γH2AX and ATM
activation
The samples of blood were initially incubated for 15 min with
anti-CD19 PE-Cy5 and anti-CD5 APC-conjugated mAb
(DAKO) at room temperature. Subsequently, the cells were
subjected to fixation and permeabilization using the IntraPrep
kit (Immunotech) following the manufacturer’s instructions.
The cells were then incubated with Ser139-phosphorylated
H2AXmAbconjugatedtoFITC(BioLegend,SanDiego,CA,
USA) or anti-phospho ATM (Ser-1981) Ab (Millipore,
Billerica,MA,USA)labeledwiththeZenonTMAlexaFluor®
488 Mouse IgG1 Labeling Kit (Molecular Probes, Eugene,
OR, USA).
Measurement of fluorescence
The fluorescence of the samples was measured using a
FACSCalibur flow cytometer (Becton Dickinson, Franklin
Lakes, NJ, USA). The CD19+/CD5+, CD19+/CD5−,o r
CD19−/CD5+ populations in the CLL samples or the CD19
+ and CD3+ populations in healthy controls were gated and
further analyzed. Ten thousand cells were measured per
sample. To determine the frequency of apoptosis, the
percentage of cells expressing active caspase-3 relative to
the control cells was calculated. The mean BCL-2 and BAX
immunofluorescence (IF) intensity was estimated for each
sample. The BCL2/BAX IF ratio for CD19+/CD5+ cells
was then calculated.
The mean γH2AX and activated ATM IF intensity was
estimated for each sample. The data obtained for drug
effects in CLL cells are presented as the drug-induced
increase in the mean γH2AX IF or ATM
P1981 IF over the
respective values determined for the control cells, which
were assessed in parallel.
Flow cytometric analysis of ZAP-70 and CD38 expression
A total of 1×10
6 peripheral blood cells were stained with
the anti-CD19 PE-conjugated MoAb (BD Pharmingen,
Franklin Lakes, NJ, USA), anti-CD5 CyChrome-
conjugated MoAb (Caltag, Burlingame, CA, USA), or
anti-CD3 PE-conjugated MoAb (BD Pharmingen). Follow-
ing membrane staining, the cells were fixed with 1%
paraformaldehyde solution in PBS for 15 min at room
temperature and permeabilized with 70% ethanol for 1 h at
−20°C. After washing with PBS, anti-ZAP-70 antibody
(Biomol Research, Plymouth Meeting, PA, USA) labeled
with the ZenonTM Alexa Fluor® 488 Mouse IgG2a
Labeling Kit (Molecular Probes) was added to the sample
tubes. The samples were incubated for 30 min, washed, and
analyzed by flow cytometry Patients were considered
positive for ZAP-70 when its expression was detected in
20% or more of the leukemic cells.
To assess CD38 expression, peripheral blood mononu-
clear cells were stained with anti-CD38 FITC, anti-CD19
PE, anti-CD5 CyChrome or IgG1 isotypic control mAbs for
20 min and analyzed by flow cytometry. Patients were
considered positive for CD38 when its expression was
detected in at least 20% of the leukemic cells.
Evaluation of the cooperative index
To evaluate the synergism between resveratrol and fludar-
abine or cladribine, a cooperative index (CI) based on the
Chou-Talalay method was calculated [14–16]. The follow-
ing formula was used: CI = sum of specific apoptosis
caused by treatment with a single agent/specific apoptosis
determined with combined treatment. The percentage of
specific apoptosis was determined using the following
formula: specific apoptosis = (drug-induced apoptosis −
spontaneous apoptosis)/(100 − spontaneous apoptosis)
100%. When CI<1, CI=1, and CI>1, the effects were
defined as synergistic, additive, and infra-additive, respec-
tively [15, 16].
Fluorescence in situ hybridization
To analyze the chromosome alterations characteristic of
CLL, locus-specific probes for 11q22.3 (LSI ATM), 17p13.1
(LSI TP53), 13q.14.3 (D13S319), and the chromosome 12
centromere (CEP12) (Abbott Diagnostics, Abbott Park, IL,
USA) were used. Fluorescence in situ hybridization (FISH)
was performed according to the manufacturer’s instructions.
Probes were denatured at 73°C for 5 min and then applied
to the designated areas of the slides. Following an overnight
hybridization at 37°C, the slides were washed and air-dried
in the dark. The slides were then stained with DAPI and
stored at −20°C in the dark. The samples were analyzed
Ann Hematol (2011) 90:173–183 175using a BX51 fluorescence microscope (OLYMPUS), and
images were captured with a CCD camera using the
CytoVision image analysis system. At least 200 nuclei
were analyzed for each probe, and the cutoff value for each
probe was 20%.
Statistical analysis
Statistical analyses were performed using STATISTICA 8.0
software for Windows. The Mann–Whitney U test was
employed for analyses of two independent groups. The
Wilcoxon test was used for analyses of two dependent
variables. p<0.05 was considered to indicate statistical
significance.
Results
Resveratrol induces apoptosis in CLL leukemic cells
derived from peripheral blood and bone marrow
Data showing the induction of apoptosis in CLL cells treated
w i t hr e s v e r a t r o le xv i v oa r ep r e s e n t e di nF i g .1a, b.W e
measured the expression of active caspase-3 in CD19+/CD5+
cells and the changes in BCL-2/BAX ratio in leukemic cells.
The percentage of cells demonstrating caspase-3 expression in
cultures treated with resveratrol for 24 h was significantly
higher than that detected in 24-h parallel control cultures.
Such an increased frequency of resveratrol-induced apoptosis
was observed in blood and bone marrow cultures, and
significantly higher levels of apoptosis were detected in bone
marrow compared to peripheral blood (Fig. 1a). The BCL-2/
BAX ratio in CD19+/CD5+ cells was significantly lower in
resveratrol-induced cultures after 24 h of treatment in
comparison to 0-h cultures (Fig. 1b).
Resveratrol induces apoptosis in leukemic cells
in a tumor-specific manner
To assess the effects of resveratrol on non-leukemic cells,
we measured the percentage of apoptotic cells that
expressed active caspase-3 within a population of CD19+/
CD5− and CD19−/CD5+ cells of CLL patients, which
represented non-leukemic B and T cells, respectively, and
within populations of CD3+ and CD19+ cells of healthy
blood donors cultured with resveratrol. The results are
shown in Fig. 1c, d. In the group of CLL patients, this
analysis was performed in nine out of 15 patients for whom
the percentage of non-leukemic cells in both peripheral
blood and bone marrow was greater than 10%. As shown in
Fig. 1c, d, no significant apoptotic effect was detected in
the population of non-leukemic lymphocytes cultured with
resveratrol, or in samples of peripheral blood or bone
marrow. Statistical analyses of the data revealed a signif-
icantly lower percentage of apoptotic cells in the group of
non-leukemic cells compared to the group of leukemic
cells, as well as in the healthy donor group compared to the
leukemic cell group.
Rates of apoptosis elicited by resveratrol in combination
with fludarabine and cladribine are higher than those
caused by a single agent
To assess the rate of apoptosis induced by resveratrol in
combination with purine analogues, the expression of active
caspase-3 in blood cells cultured with resveratrol + fludar-
abine or resveratrol + cladribine was measured. As shown in
Fig. 2a, the frequency of apoptosis in resveratrol +
fludarabine-treated cultures was significantly greater than
those in resveratrol-treated and fludarabine-treated cultures.
Similarly, a significant increase in apoptosis was observed in
resveratrol + cladribine-treated cultures compared to resver-
atrol cultures and to cladribine cultures (Fig. 2a). To evaluate
the effect of the combined action of resveratrol and purine
analogues, the CI for each sample was evaluated and is
presented in Fig. 2b. In 14 out of 18 resveratrol + fludarabine
combinations and in 15 out of 18 resveratrol + cladribine
combinations, a synergic effect was observed.
Resveratrol-induced apoptosis in CLL cells differs
in patients with better prognostic markers vs those
with worse prognostic markers
To assess whether the rate of apoptosis caused by
resveratrol is associated with the prognosis of CLL, the
percentages of apoptotic cells were compared between
patients with worse prognostic markers (ZAP-70+, CD38+,
advanced 2–4 stages according to the Rai classification,
17p13.1 or 11q22.3 genetic abnormalities) and those with
better prognostic markers (ZAP-70−, CD38−, early 0–1
stages according to the Rai classification, 13q14.3 or
trisomy 12 genetic abnormalities, or an absence of genetic
changes). We detected a higher percentage of apoptotic
caspase-3-positive cells in resveratrol-induced cultures from
patients with low-risk markers in comparison to those in the
higher-risk group, and the results are shown in Fig. 3. The
rates of apoptosis in cultures treated with resveratrol
together with purine analogues differed only between the
group of patient with low-risk cytogenetic changes and that
with high-risk abnormalities, with significantly higher
values detected in the former group. With respect to
cultures treated with resveratrol together with purine
analogues, we did not detect significant differences in the
rate of apoptosis between the ZAP-70− and the ZAP-70+
group, the CD38− and the CD38+ group or the 0–1 Rai and
the 2–4 Rai group.
176 Ann Hematol (2011) 90:173–183Resveratrol induces phosphorylation of H2AX
and activation of ATM in CLL malignant cells
To assess whether resveratrol causes DNA damage, the
expression of phosphorylated H2AX and activated ATM in
CD19+/CD5+cellswasmeasured.Inmostcases,anincreasein
γH2AX expression concurrent with increased expression of
activated ATM was detected after a 2-h incubation with
resveratrol, as compared to the expression levels of these
phosphoproteins in control cultures. We detected a statistically
significant correlation between γH2AX expression and acti-
vated ATM expression (R=0.57, p=0.01) (Fig. 4b). Data
showing the increase in γH2AX and activated ATM
expression compared to their expression levels in control
cultures of cells from individual patients, as well as
representative histograms showing the expressions, are pre-
sented in Fig. 4. As presented in Fig. 4a, however, the cells
from a few patients remained unaffected. The expression of
γH2AX was also significantly higher in the ZAP-70−,0 –1
Rai stadium and better cytogenetic abnormalities groups in
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Fig. 1 a Percentage of apoptotic leukemic cells in 24-h cultures with
resveratrol in samples of peripheral blood and bone marrow.
Statistically significant differences are indicated. b BCL-2/BAX ratio
of CD19+/CD5+ cells in cultures treated with resveratrol for 24 h
compared to the control 0-h culture. A decreased ratio was detected in
resveratrol-induced cultures after 24 h. Statistically significant differ-
ences are indicated. c Percentage of apoptotic cells in populations of
non-leukemic B (CD19+/CD5−) and T (CD19−/CD5+) cells from the
chosen CLL patients (n=9) and healthy donors (n=5) in comparison to
a population of leukemic CD19+/CD5+ cells in ex vivo peripheral
blood cultures treated with resveratrol. Data represent the drug-induced
increase in the percentage of apoptotic cells above the respective
values observed in control cultures of the same cell population. Single
and double asterisks indicate statistically significant differences of p=
0.0001 and p=0.002, respectively, in comparison to the CD19+/CD5+
population. d Percentage of apoptotic cells in populations of non-
leukemic B and T cells from the chosen CLL patients compared to the
leukemic CD19+/CD5+ cell population in ex vivo bone marrow
cultures with resveratrol. Data represent the drug-induced increase in
the percentage of apoptotic cells above the respective values observed
in control cultures of the same cell population. Asterisk indicates
statistically significant differences of p=0.0001 in comparison to the
CD19+/CD5+ population. Graphs represent the median ± minimum/
maximum
Ann Hematol (2011) 90:173–183 177comparison to the ZAP-70+, 2–4 Rai stadium and worse
cytogenetic changes groups, respectively. We also compared
the rate of apoptosis in response to resveratrol in the group of
patients in which an increase in γH2AX expression above its
“constitutive” level was observed (“γH2AX positive”, num-
ber of patients=12) and in the group that demonstrated no
increase in γH2AX expression (“γH2AX negative”, number
of patients=6). The rate of apoptosis was higher in the
“γH2AX positive” group than in the “γH2AX negative”
group (4.7±1.7 vs 2.9±1.4, p=0.003, and 10.5±5.1 vs 5.2±
2.1, p=0.004, for peripheral blood and bone marrow,
respectively).
Discussion
One of the most important biological activities of resver-
atrol is its cancer-chemopreventive and anti-cancer proper-
ties [17]. Resveratrol has been shown to suppress the in
vitro proliferation of a variety of tumor cells [5, 18]. Its
anti-proliferative activity is associated with the perturbed
cell transit through G0-1 phase of the cell cycle and with
the induction of apoptosis. It has also been reported that
resveratrol inhibits the activity of ribonucleotide reductase,
the enzyme that provides proliferating cells with the
deoxyribonucleotides required for DNA synthesis during
early S phase of the cell cycle, which leads to an inhibition
of DNA synthesis [19, 20]. Resveratrol affects other critical
events associated with tumor development, such as the up-
regulation of p53 and p21 levels, induction of nitric oxide,
inhibition of cyclooxygenase, protection against reactive
oxygen intermediates, down-regulation of survival factors,
and down-regulation of proteinases [21, 22].
Thesepropertiesofresveratrol ledustoassessits effects on
leukemic cells of CLL patients. Our results indicated that
resveratrol caused apoptosis in leukemic CD19+/CD5+ cells
in both the peripheral blood and bone marrow in a tumor-
specific manner. Non-leukemic cells were not significantly
affected. We also showed that apoptosis caused by resveratrol
wasassociatedwiththeregulationofBCL-2andBAXprotein
expression, resulting in a decreased BCL-2/BAX ratio.
Resveratrol-induced apoptosis of CLL cells was first de-
scribed by Roman et al. [23]. They showed that resveratrol
caused apoptosis of leukemic CLL cells and that this effect
could be mediated by the down-regulation of two anti-
apoptotic proteins, inducible nitric oxide synthase (iNOS)
and BCL-2, whereas apoptosis of normal lymphocytes was
not observed [23]. The authors continued their research by
assessing other polyphenols and flavones with respect to
their influence on CLL and normal lymphocytes and
a
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Fig. 2 a Percentage of apoptotic leukemic cells in cultures treated
with resveratrol, fludarabine, and resveratrol combined with fludar-
abine for 24 h and the CI calculated for each sample. b Percentage of
apoptotic leukemic cells in cultures treated with resveratrol, cladribine,
and resveratrol combined with cladribine for 24 h and the CI
calculated for each sample. Data represent the drug-induced increase
in the percentage of apoptotic cells compared to the respective values
observed in parallel control cultures. CI = (sum of specific apoptosis of
single agent treatment/specific apoptosis of combined treatment). The
percentage of specific apoptosis was determined using the following
formula: specific apoptosis = (drug induced apoptosis − spontaneous
apoptosis)/(100 − spontaneous apoptosis) × 100%. When CI<1, CI=1,
and CI>1, the effects were defined as synergistic, additive, and infra-
additive, respectively
178 Ann Hematol (2011) 90:173–183confirmed the role of these substances as inducers of CLL
tumor-specific apoptosis [24, 25]. In the present study, the
anti-apoptotic effects of resveratrol were analyzed in suspen-
sion cultures, which have been commonly used by other
researchers in in vitro experiments to assess the effects of
drugs. However, it has been recently reported that CLL cells
are protected against the activity of drugs in the tissue
microenvironment, such as the bone marrow and secondary
lymphoid organs. It could be associated with drug resistance
or could pave the way to disease relapse [26, 27]. Thus,
further studies in the presence of microenvironment cells,
such as bone marrow stromal cells, are required to assess the
precise mechanism of resveratrol action. The results of the
present study, however, undoubtedly confirm the anti-
apoptotic effects of resveratrol on leukemic cells in suspen-
sion and its potential to reduce the number of leukemic cells
in peripheral blood in vivo. Taking these findings into
account, resveratrol may be considered a good therapeutic
option, especially in older CLL patients for whom there are
some limitations to the use of aggressive treatment, and a
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Fig. 3 a Percentage of apopto-
tic leukemic cells in cultures
treated with resveratrol for 24 h
in the group of ZAP-70−
patients (n=11) and in the group
of ZAP-70+ patients (n=7). b
Percentage of apoptotic leuke-
mic cells in cultures treated with
resveratrol in the group of
CD38− patients (n=7) and in
the group of CD38+ patients
(n=10). c Percentage of apopto-
tic leukemic cells in cultures
treated with resveratrol in the
group of patients with 0–1 sta-
dium (n=6) and in the group
patients with 2–4 stadium (n=
12) according to the Rai classi-
fication. d Percentage of apo-
ptotic leukemic cells in cultures
treated with resveratrol in the
group of patients with standard-
risk cytogenetic changes
(13q14.3, trisomy 12 or no
changes detected, n=5) and in
the group of patients with high-
risk cytogenetic changes
(17p13.1 or 11q22.3, n=4). The
percentage of apoptotic leuke-
mic cells was calculated above
the level in control cultures.
Statistically significant differen-
ces are indicated in the figure.
Graphs represent means ±
standard deviations. NS, not
statistically significant
Ann Hematol (2011) 90:173–183 179reduction of lymphocytosis is often an acceptable effect of
therapy.
In the next part of our study, we analyzed the effects of
resveratrol in combination with the purine analogues
fludarabine and cladribine on the induction of apoptosis.
This is the first report to describe a rate of apoptosis caused
by resveratrol in combination with purine analogues that is
higher than that caused by a single drug. Based on the CI,
we assessed the effect of the combined treatment, which
was synergistic in most of the analyzed cases.
Purine analogues are widely used for the treatment of
CLL, and it has been reported that higher remission rates
can be obtained when they are employed as a first-line
therapy [28, 29]. Two purine analogues—fludarabine and
cladribine—have been proven to possess antitumor activity,
as evidenced by a direct interference with DNA and RNA
synthesis, interference with DNA repair mechanisms,
induction of apoptosis, and regulation of the cell cycle
and signal transduction pathways [30, 31]. However, some
patients are refractory to these drugs. Other problems
a
b
c
Fig. 4 a Ex vivo induction of
γH2AX and phosphorylated
ATM (ATM
P1981) in CD5+/
CD19+ cells treated with
resveratrol for 2 h. Data repre-
sent the drug-induced increase
in expression of γH2AX
(γH2AX IF) and activated ATM
(ATM
P1981 IF) compared to the
respective values observed in
parallel control cultures. No in-
crease in γH2AX expression
after resveratrol treatment was
detected in leukemic cells of
patient nos. 2, 5, 6, 7, 8, and 9.
No increase in expression of
ATM
P1981 after resveratrol treat-
ment was detected in leukemic
cells of patient nos. 2, 3, 5, 6, 8,
and 9. In patient no. 7, a slight
increase in ATM
P1981 expression
was observed, but no increase in
ATM
P1981 expression was
detected in patient no. 3. b
Diagram showing the correla-
tion between γH2AX and
ATM
P1981 expression. c Repre-
sentative flow cytometric histo-
grams showing the expression
of γH2AX and ATM
P1981 in
CD5+/CD19+ cells treated with
resveratrol for 2 h
180 Ann Hematol (2011) 90:173–183associated with the use of purine analogues are associated
with their toxicities, for example, immunosuppression with
a decrease in the CD4+/CD8+ ratio, which leads to the
development of opportunistic infections, myelosuppression,
and gastrointestinal toxicities, including nausea, vomiting
and hepatic lesions [16, 32, 33]. Thus, the reduction of
purine analogue-associated toxicity achieved with a lower
dose may be of great importance. Because of the combined
effects of resveratrol and both fludarabine and cladribine,
lower purine analogue doses in combination with resvera-
trol are possible. Such a combination of purine analogues
with other drugs like thalidomide or valproate has been
reported in CLL patients based on in vitro experiments and
clinical trials [16, 34–36].
CLL is a heterogeneous disease with a variable clinical
course and prognosis. Thus, the roles of prognostic factors
in CLL are very important, especially in distinguishing the
group of patients that require intensive treatment from those
who will benefit from milder forms of therapy. A number of
prognostic markers have been identified in CLL patients,
and among them, markers related to the biology of the
disease, such as genomic aberrations, gene abnormalities,
the mutation status of the variable segment of immuno-
globulin heavy chain genes (IgVH), and surrogate markers
like ZAP-70 and CD38 expression have been described as
the most powerful ones [37–40].
In the present study, we tried to assess whether the rate
of apoptosis caused by resveratrol differed between patients
with better and worse prognostic markers. We detected
differences in the percentage of resveratrol-induced apo-
ptotic rates between the group of patients with ZAP-70−,
CD38−, early clinical stages, and standard-risk cytogenetic
changes in comparison to the group with ZAP-70+, CD38
+, advanced clinical stages, and high-risk cytogenetic
abnormalities, which indicated better pro-apoptotic effects
in the former group. We can suppose that treatment with
resveratrol may be most effective in patients with better
prognostic factors and in early stages of the disease.
Interestingly, there were no significant differences between
both groups with respect to resveratrol in combination with
purine analogues, excluding the group with standard-risk
cytogenetic changes compared to that with high-risk
cytogenetic changes. Thus, resveratrol combined with
purine analogues can be equally effective in CLL patients,
independently of ZAP-70 expression, CD38 expression,
and clinical stadium according to the Rai classification.
Among the different activities of resveratrol, its antiox-
idant potential has generated some controversy. Resveratrol
is indicated as an agent that possesses protective effects
against oxidative stress. It is both a free radical scavenger
and a potent antioxidant based on its ability to promote the
activities of a variety of antioxidant enzymes [6, 41].
However, subsequent research has provided new, interest-
ing insight into the effect of resveratrol on the intracellular
redox state. These results seem to support both anti- and
pro-oxidant activities of resveratrol, depending on the
concentration of resveratrol and the cell type [6]. It has
been proposed that such a pro-oxidant action of resveratrol
could be an important mechanism of its anticancer and
apoptotic-inducing effects [6]. Ahmad et al. [42] reported
that resveratrol elicited pro-oxidant properties, as evidenced
by an increase in the intracellular concentration of
superoxide. DNA damage induced by resveratrol in the
presence of copper ions has been reported by Zheng et al.
[43]. Similarly, DNA degradation by resveratrol alone or in
the presence of copper has been demonstrated in human
peripheral blood lymphocytes by Azmi et al. [44, 45].
The phosphorylated histone H2AX (γH2AX) is a
marker of double-stranded DNA breaks, whereas ATM
kinase is considered a major physiological mediator of
H2AX phosphorylation. ATM activation occurs via its
autophosphorylation at Ser1981 [46, 47]. A few studies
have examined the influence of resveratrol on H2AX
phosphorylation. Tyagi et al. [48] reported that resveratrol
treatment increased the level of phosphorylated γH2AX via
ATM/ATR kinases. Rusin et al. [49] examined the influence
of resveratrol on the growth of human cancer cell lines and
its modulation of the expression of key proteins involved in
DNA repair and cell cycle regulation. Their results showed
that resveratrol induced DNA damage, as evidenced by the
phosphorylation of histone H2AX and p53 protein.
In the present study, the expression of both phosphory-
lated H2AX and activated ATM in CD19+/CD5+ cells were
examined using flow cytometry. We observed an increase in
γH2AX expression together with an elevation of activated
ATM in the same samples. Interestingly, this increase was
observed in most but not all cases. The analysis of γH2AX
expression in the group with worse vs better prognostic
markers revealed an association with prognostic factors,
such as ZAP-70 and CD38 expression, clinical stadium of
disease, and cytogenetic abnormalities. A significantly
higher expression level of γH2AX was detected in patients
with better prognostic markers. Thus, it can be concluded
that more aggressive cases of CLL associated with an
unmutated IgVH region or cytogenetic abnormalities,
which involve proteins that play a role in the DNA damage
response, such as p53 or ATM kinase, are more resistant to
DNA damage caused by resveratrol. Furthermore, in the
group of patients exhibiting H2AX phosphorylation, a
significantly higher percentage of apoptosis caused by
resveratrol was observed, as compared to the group with
no detectable H2AX phosphorylation. Thus, phosphoryla-
tion of H2AX makes the cells more prone to apoptosis and
might be used as a predictor of apoptosis sensitivity.
In conclusion, the obtained results indicate that resver-
atrol alone and in combination with purine analogues
Ann Hematol (2011) 90:173–183 181warrants further study as a new therapeutic option for CLL
patients. This naturally occurring substance may be
especially useful in older patients for whom there are some
limitations on the use of aggressive treatments. On the other
hand, there is a possibility of using lower doses of purine
analogues in combination with resveratrol because of their
combined effect. The mechanisms of resveratrol action
appear to be complex and remain to be precisely estab-
lished. One of mechanisms in question is the induction of
DNA damage, which ultimately leads to apoptosis.
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